Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06651229
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-18
Brief Title:
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 First-in-Human Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of Part 1 Dose Escalation of the study is to assess the effective dose recommended Phase 2 doses RP2Ds that can be safely administered and dosing regimens of JNJ-90189892 in participants with relapsed or refractory RR acute myeloid leukemia AML or RR higher-risk type of myelodysplastic neoplasms type of cancer of the blood and bone marrow which does not respond to treatment or comes back after treatment The purpose of Part 2 Cohort Expansion is to further assess the safety tolerability and efficacy in participants with RR AML or higher-risk types of MDS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None